1Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in health volunteers[ J ]. Eur J Clin Pharmacol, 1999,55 : 199 - 203.
2Lindholm A, McEwen J, Riis AP. Improved postprandial glycaemic control with insulin aspart-randomized double-blind crossover trial in type 1 diabetes mellitus [ J ]. Diabetes Care,1999,22 : 801 - 805.
3Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients[ J ], Diabetes Care, 1998,21 : 1901 - 1909.
4Colagiuri S, Heller S, Vaaler B, et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with type 1 dianbetes[J]. Diabetologia ,2001,44(Suppl 1) :A210.
5Data from the UK Prospective Diabetes Study presented at 34th Annual Meeting,European Society for the study of Diabetes[ R].Barcelona, Spain, 1998.
6Vajo Z, Duckwonh WC, Genetically engineered insulin analogs: diabetes in the new millennium [J]. Pharmacol Rev, 2000,52 (1):1-9.
7Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus [J]. Ann Pharmacother, 1996,30(11):1263-1271.
8Anderson JH, Brunelle RL, Koivisto VA, et al.Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment [J]. Diabetes, 1997,46:265-270.
9White JR, Campbell RK, Recent developments in the pharmacological reduction of blood glucose in patients with type2 diabetes [J]. Clinical Diabetes, 2001,19:153-159.
10Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type1 diabetes [J]. Diabetes Care, 2000,23(5):639-643.
